Article

What Should Specialty Pharmacists Know About the ReDOS Clinical Trial?

Conference|Gastrointestinal Cancers Symposium

Tanios Bekaii-Saab, MD, FACP, Mayo Clinic Cancer Center, talks about key takeaways from the phase 2 ReDOS clinical trial for specialty pharmacists.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Lenacapavir | Image Credit: luchschenF | stock.adobe.com
Related Content
Motor neuron connecting to muscle fiber, 3D illustration
September 3rd 2025

Study: Apitegromab Meaningfully Improves Motor Function in Spinal Muscular Atrophy

Luke Halpern, Assistant Editor
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
September 3rd 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
Skin disorder, pepper appearance from scleroderma, autoimmune disease male hand Skin disorder pepper appearance from vitiligo,scleroderma raynaud, medical concept autoimmune disease.
September 3rd 2025

Patients With Systemic Sclerosis Face Decreased HDL-C, Increased Lipoprotein(a)

Luke Halpern, Assistant Editor
Pharmacy Focus: Oncology Edition – Key Insights and Interviews From the 2024 SABCS Meeting
September 3rd 2025

Pharmacy Focus: Oncology Edition – Key Insights and Interviews From the 2024 SABCS Meeting

Alexandra Gerlach, Associate Editor
High-density lipoprotein particles(HDL) also known as good cholesterol, in the blood. Higher HDL levels correlate with lower risk of cardiovascular disease
September 3rd 2025

Elevated High-Density Lipoprotein Cholesterol May Reduce Risk of Stress Urinary Incontinence

Luke Halpern, Assistant Editor
FDA logo on smartphone -- Image credit: gguy | stock.adobe.com
September 3rd 2025

FDA Issues CRL to Vatiquinone NDA Indicated For Friedreich Ataxia

Gillian McGovern, Associate Editor